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A B S T R A C T
The aim of the present study is to elucidate the neuronal pathways associated to NSAIDs causing a reduction of
the risk and progression of Alzheimer's disease. The research was developed administering the active enantiomer
of ibuprofen, dexibuprofen (DXI), in order to reduce associated gastric toxicity. DXI was administered from three
to six-month-old female APPswe/PS1dE9 mice as a model of familial Alzheimer's disease. DXI treatment reduced
the activation of glial cells and the cytokine release involved in the neurodegenerative process, especially TNFα.
Moreover, DXI reduced soluble β-amyloid (Aβ1-42) plaque deposition by decreasing APP, BACE1 and facilitating
Aβ degradation by enhancing insulin-degrading enzyme. DXI also decreased TAU hyperphosphorylation in-
hibiting c-Abl/CABLES/p-CDK5 activation signal pathway and prevented spatial learning and memory impair-
ment in transgenic mice. Therefore, chronic DXI treatment could constitute a potential AD-modifying drug, both
restoring cognitive functions and reversing multiple brain neuropathological hallmarks.
1. Introduction
Alzheimer's disease (AD) is the most common form of dementia
aﬀecting elderly people [1]. AD is clinically characterized by loss of
memory and cognitive functions. Moreover, histopathological hall-
marks include extracellular amyloid peptide (Aβ) deposition in neuritic
plaques, and intracellular deposits of hyperphosphorylated TAU (pT-
AU), causing the formation of neuroﬁbrillary tangles (NFTs) and, ﬁ-
nally, neuronal loss [2].
Despite its high prevalence and mortality, the molecular mechan-
isms associated with neuronal loss are still unknown. However, Aβ
peptides, especially Aβ(1-42), are currently considered the main neu-
rotoxins responsible for AD neuronal loss. According to the amyloido-
genic cascade hypothesis, Aβ peptides are generated via the amyloid
precursor protein (APP) through two proteolytic enzymes, the β-se-
cretase 1 (BACE1) and the γ-secretase [3,4].
Since there are no eﬀective treatments to prevent or cure AD, great
eﬀorts are currently directed towards identifying disease-modifying
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therapies, involving several compounds in diﬀerent phases of devel-
opment [5–7]. However, due to the complex nature of AD, one of the
main concerns in drug development relies on the ability to obtain
compounds capable of acting in more than a single speciﬁc disease
target. Thereby, some researchers propose that the popular amyloid
cascade hypothesis should be slightly modiﬁed to incorporate addi-
tional cellular and physiological components contributing to the neu-
rodegenerative process, such as neuroinﬂammatory glial cells [5,7].
This hypothesis suggests that glial activation, mainly microglia, would
lead to an upregulation of brain cytokines and chemokines such as IL-
1β, IL-12, tumor necrosis factor (TNFα), and inducible nitric oxide
synthase activation (iNOS), thus causing neuronal loss in diﬀerent brain
areas, especially the hippocampus [6,8].
Nevertheless, the dual eﬀects of the inﬂammatory response add
complexity to the process. At the beginning of the disease, inﬂamma-
tion constitutes a neuroprotective response intended to reduce Aβ ac-
cumulation. However, as the disease progresses, the excessive or
chronic neuroinﬂammatory response contributes to AD development
[7]. For this reason, non-steroidal anti-inﬂammatory drugs (NSAIDs)
are being on the research focus towards AD treatment over the last
years [9]. These drugs might inﬂuence the inﬂammatory response by
activating the peroxisome proliferator-activated receptor-γ (PPARγ)
and inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-
2). In addition, some studies have revealed other interesting NSAIDs
targets, such as nuclear factor kappa beta (NFĸβ) and β and γ-secretases
[8]. In addition, some authors reported that these beneﬁts may only be
observed in early phases of the disease [6]. Although there are still
some discrepancies between epidemiological results, some studies in-
dicate that patients under long-term treatment with NSAIDs for other
conditions such as rheumatoid arthritis, present a reduced incidence of
AD, suggesting that these drugs could restore some pathways altered in
the disease [10,11].
Ibuprofen (IBU) is one of the most commonly used NSAIDs.
Preclinical studies with IBU showed a reduction in the levels of pTAU
and Aβ deposition, as well as a decrease in COX-2 expression and ac-
tivated microglia [12]. Moreover, a reduction in oxidative stress
Fig. 1. A) Representative GAPDH-normalized immunoblotting images and quantiﬁcation (n = 4–6 independent samples per group) of proteins related in neuroinﬂammation processes in
the hippocampal extracts of WT, APP/PS1 and APP/PS1-DXI treated 6-month-old mice. B) Immunohistochemistry of ThS of Aβ plaque and GFAP in the brains of 6-month-old APP/PS1
and APP/PS1-DXI treated mice (n = 4–6 independent samples per group, with at least 5 slices analyzed per sample). C) Concentrations of soluble and insoluble human Aβ(1−42)
peptides in the cortical extracts in untreated and DXI-treated APP/PS1 mice, expressed as pg/mg of total protein as determined by ELISA; n = 4–6 independent samples per group, with 3
technical replicates per sample (* denotes p< 0.05).
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through a decrease in NOX2 and 4HNE expression was also reported
[12]. Bearing in mind these promising ﬁndings, in the present study we
investigated the eﬀects of dexibuprofen (DXI), the active enantiomer of
IBU [13]. DXI provides an improvement for the treatment of several
inﬂammatory diseases, since lower doses than its racemic counterpart
are necessary to obtain identical therapeutic eﬃcacy [14]. Further-
more, the higher solubility in water and increased absorption of DXI
allow to reduce undesirable ulcerogenic side eﬀects associated with IBU
or other NSAIDs [14–16]. Additionally, preclinical data have demon-
strated that DXI have a more powerful anti-inﬂammatory and analgesic
eﬀect than IBU [17]. Taking into account the advantages of this com-
pound, the aim of the present study was to investigate the eﬀects of DXI
on AD-associated neuropathology markers, as well as the underlying
mechanisms related to memory loss, in female APPswe/PS1dE9 mice, a
model of familial AD [18,19].
2. Materials and methods
2.1. Animals and treatment
In this study, six-month-old female APPswe/PS1dE9 (APP/PS1) and
C57BL/6 wild-type (WT) mice were used. This animal model was
chosen according to previous studies reporting that female mice de-
velop higher progressive memory impairment and AD-like neuro-
pathology compared to male mice [20]. These transgenic mice express a
Swedish (K594M/N595L) mutation of a chimeric mouse/human APP
(mo/huAPP695swe), together with the human exon-9-deleted variant
of PS1 (PS1-dE9).
Animals were divided in three groups (WT, APP/PS1 and APP/PS1
DXI) and, at least, 10 animals per group were used. APP/PS1 transgenic
mice were non-treated (APP/PS1) or treated with water supplemented
with DXI (APP/PS1 DXI), containing 50 mgDXI kg−1 day−1 for 3 months
before sacriﬁce. WT mice did not receive any pharmacological treat-
ment. All animals were given access to food or water ad libitum and kept
under controlled temperature, humidity and light conditions. Every
eﬀort was made to reduce the number of animals and minimize animal
suﬀering. Mice were treated in accordance with the European
Community Council Directive 86/609/EEC and the procedures estab-
lished by the Department d′Agricultura, Ramaderia i Pesca of the
Generalitat de Catalunya.
2.2. Cognitive function test: novel object recognition
Before sacriﬁce, the hippocampal-dependent recognition memory of
treated and non-treated mice was assessed by a novel object recognition
test (NORT). The ﬁrst three days, each mouse was left to get used to the
open ﬁeld box, without any objects (10 min/session). On the fourth
day, mice were left for 10 min to explore two identical objects (A+A).
On the ﬁfth day, each mouse was exposed for 10 min to a familiar
object A and a novel object, namely B. After this, the objects and the
open ﬁeld box were cleaned with soap and water in order to avoid the
presence of olfactory signs. Recorded videos were analyzed and the
discrimination index (DI) was calculated dividing the exploration time
of the novel object by the total exploration time [21] Exploration was
deﬁned as sniﬃng or touching an object. Mice with a total exploration
time of< 5 s for an object were removed from analyses [22].
2.3. Immunoﬂuorescence
Mice were sacriﬁced at 6 months and, at least, 5 animals of each
group were perfused before brain extraction using 4% paraformalde-
hyde (PFA). Tissues were processed and stained as previously described
Fig. 2. A) Representative GAPDH-normalized immunoblotting images and quantiﬁcation (n = 4–6 independent samples per group) of key molecules involved in APP processing APP,
BACE, ADAM10 and IDE in the hippocampal extracts of WT, APP/PS1 and APP/PS1-DXI treated 6-month-old mice (* denotes p< 0.05, ** denotes p< 0.01). B) Quantitative analysis of
mRNA expression of ADAM10 and BACE1 determined by RT-PCR.
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by our group [23,24]. The antibodies used in this study are supplied as
Table 1 of Supplementary material.
2.4. Measurement of β-amyloid peptides in cortical tissues by ELISA
Soluble and insoluble Aβ (1−42) were measured in cortical extracts
using commercially available human ELISA kits (Cat # KHB3441;
Invitrogen, Camarillo, CA, USA) according to manufacturer's guide-
lines. Data obtained from the cortical homogenates was expressed as
picograms of Aβ content per milligrams of total protein (pg/mg) [25].
2.5. Sample preparation for Western blotting and Real-Time PCR
At 6 months, 5–8 animals of each group were sacriﬁced by cervical
dislocation prior to brain dissection. For protein extraction, hippocampi
were homogenized in lysis buﬀer (50 mM TrisHCl pH: 7.4, 150 mM
NaCl, 5 mM EDTA, 1%Triton X-100) and protease inhibitor mixture
(Complete, Roche Diagnostics, Barcelona, Spain). Samples were stored
at−80 °C until use. Protein concentration was determined using Pierce
BCA Protein Assay kit (Pierce Company, Rockford, MI, USA) [26].
Fig. 3. Representative GAPDH-normalized immunoblotting images and quantiﬁcation (n = 4–6 independent samples per group) of key molecules involved in TAU hyperphosphorilation
A) Protein levels of TAU, pTAU (T205), pTAU(S396) and pTAU (S404) of WT, APP/PS1 and APP/PS1 treated with DXI, B) Protein levels of c-ABL, p-c-ABL (Y412), CABLES, CDK5 and
pCDK5(Y15) of WT, APP/PS1 and APP/PS1 treated with DXI and C) Protein levels of AKT, pAKT, GSK3β AND PGSK3β of WT, APP/PS1 and APP/PS1 treated with DXI (* denotes
p<0.05, ** denotes p<0.01).
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2.6. Western blot analysis
Aliquots of samples containing 10 µg of protein were analyzed by
Western Blotting. The samples were placed in sample buﬀer (0.5 M Tris-
HCl, 10% glycerol, 2% SDS, 5% 2-mercaptoethanol, 0.05% bromo-
phenol blue, pH 6.8) and denatured by boiling at 95 °C for 5 min.
Samples were separated by electrophoresis on 10% acrylamide gels,
transferred to PVDF (Polyvinylidene diﬂuoride) membranes using
transblot apparatus and blocked in 5% skim milk powder in TBS-T
buﬀer (50 mM Tris, 1.5% NaCl, 0.05% Tween 20, pH 7.5) for 1 h at
room temperature. They were incubated overnight at 4 °C with primary
antibodies (Supplementary material, Table 2). After that, membranes
were washed in TBS-T buﬀer and incubated with IgG secondary anti-
body for 1 h at room temperature. Bands were detected by chemilu-
minescence detection kit and using Chemi doc XRS +Molecular Imager
detection system (Bio-Rad). The quantiﬁcation was performed by Image
Lab image analysis software. All results were normalized to GAPDH
[26].
2.7. Real-Time PCR
For RNA extraction, hippocampi were homogenized by Trizol re-
agent (Life Technologies Corporation) and samples were stored at
−80 °C until use. Equal concentrations of cDNA of each animal were
used for q-PCR and each sample was analyzed by triplicate. The assays
were performed on a StepOnePlus Real-Time PCR system (Applied
Biosystems). The PCR reaction contained 2 µg of reverse-transcribed
RNA, 2SYBRGreen qPCR Master Mix (K0253, Pierce, Thermo Fisher
Scientiﬁc), and 100 mM of each primer. Analyzed genes are detailed in
Table 3 of Supplementary material. Results were normalized to actin
[26].
2.8. Gastric damage
After treatment, mice were sacriﬁced and stomachs were removed,
cut and rinsed with ice-cold distilled water. The ulcer index (UI) was
determined by calculating the severity of the lesions as previously
Fig. 4. Novel object recognition test. A) Discrimination index (DI) expressed as a per-
centage comparison between WT, APP/PS1 and APP/PS1 DXI. B) No signiﬁcant eﬀect on
total exploration time during the test was found between the assessed groups (* denotes
p<0.05).
Fig. 5. A) Representative GAPDH-normalized immunoblotting images and quantiﬁcation (n = 4–6 independent samples per group) of proteins related to memory processes in the
hippocampal extracts of WT, APP/PS1 and APP/PS1 treated with DXI in 6-month-old mice. (* denotes p< 0.05). B) Immunohistochemistry of synaptophysin and Hoestch in the
hippocampal CA3 region.
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reported by other authors [27].
2.9. Statistical analysis
Statistical analyses were performed using GraphPad Prism 6. Data
were expressed as mean± standard deviation. Signiﬁcant diﬀerences
were determined by one-way analysis of variance (ANOVA), followed
by Tukey's post hoc test for multigroup comparisons to compare data
from the experimental groups. The level of signiﬁcance for the accep-
tance was p<0.05.
3. Results
3.1. Dexibuprofen reduces neuroinﬂammation in APPswe/PS1dE9 mice
brain
It is well known that activated astrocytes and microglia are usually
localized in the brain area where Aβ deposition occurs in APP/PS1 mice
[28]. We found a signiﬁcant increase in NFκβ, TNFα, iNOS and neu-
ronal Nitric Oxide Synthase (nNOS) protein level in APP/PS1 mice
compared to WT (p<0.05; Fig. 1A). In addition, DXI treatment sig-
niﬁcantly decreased the levels of all these proteins, with the exception
of nNOS (no signiﬁcant diﬀerences were observed).
In order to study the astrocytes activation, brain sections were im-
munostained with an anti-GFAP (Glial Fibrillary Acidic Protein) anti-
body. The staining against GFAP was markedly higher in the brain of
untreated APP/PS1 mice compared to DXI treated mice (Fig. 1B).
Additionally, potential gastric damage of DXI was compared using
the same dose of it's racemic counterpart, IBU, in WT mice for three
months. In agreement with other authors, DXI induced signiﬁcantly less
gastric damage than IBU (Supplementary material Fig. 1).
3.2. Dexibuprofen reduces plaque burden and inhibits APP processing
toward the amyloidogenic pathway in APPswe/PS1dE9 mice
APP/PS1 mice exhibit a time-dependent Aβ production and de-
position in the brain with increasing age [29]. To determine the eﬀect
of DXI treatment on this process, Thioﬂavin-S (ThS) was used for de-
tection of ﬁbrillary plaques (Fig. 1B). The analysis revealed that long-
term administration of DXI signiﬁcantly reduced the area occupied by
ﬁbrillary plaques in the cerebral cortex of APP/PS1 mice. Additionally,
as shown in Fig. 1C, DXI treatment caused a signiﬁcant decrease in the
levels of soluble and insoluble Aβ (1-42) (p<0.05).
Western Blot analyses were carried out to investigate the mechan-
isms involved in APP processing that contribute to Aβ soluble
production. Quantitative analysis (Fig. 2A) indicated that the levels of
full-length APP were signiﬁcantly increased in the hippocampus of non-
treated transgenic group (p<0.01), whereas a signiﬁcantly decrease in
the levels of this protein was found in DXI-treated mice (p<0.01). In
addition, DXI signiﬁcantly decreased protein levels of BACE1 in the
hippocampus of transgenic mice compared to non-treated APP/PS1
mice (p<0.001). Moreover, DXI treatment signiﬁcantly increased IDE
protein levels in APP/PS1 mice hippocampus (p<0.05). However,
changes in ADAM10 in APP/PS1 mice after DXI treatment were not
observed. As it is shown in Fig. 2B, no signiﬁcant diﬀerences between
mRNA expression of ADAM10 nor BACE1 were observed after DXI
treatment. Therefore, these results indicate that DXI inhibits APP pro-
cessing toward amyloidogenic pathway, thus suggesting that DXI
lowers the plaque burden by promoting Aβ degradation through the
inhibition of BACE1 and the synthesis of APP in the brain hippocampus
of transgenic mice.
3.3. Dexibuprofen attenuates TAU phosphorylation in APPswe/ PS1dE9
mice
The eﬀects of DXI on TAU hyperphosphorylation were assessed by
Western blot. Data analysis showed that the levels of pTAU at Thr205
and Ser 396 were signiﬁcantly decreased in the hippocampus of DXI
APP/PS1 mice compared with non-treated transgenic mice
(p<0.0001; p<0.001 respectively; Fig. 3A).
The process of TAU hyperphosphorylation is mediated mainly by
two kinases: the cyclin-dependent kinase 5 (CDK5) and the glycogen
synthase kinase 3β (GSK3β). In addition, upstream regulation of both
kinases is mediated by c-ABL. Thus, analysis of the c-ABL signaling
pathway in the hippocampus at 6 months revealed an increase in the
protein levels of total and phosphorylated c-ABL on Tyr412 in APP/PS1
compared with WT mice (p<0.05; p<0.01; Fig. 3B). Moreover,
consequently with the c-ABL-dependent CDK5 activation, CDK5Tyr15
phosphorylation was also markedly elevated (p<0.05). Furthermore,
in this signaling pathway, CABLES mediates the interaction between c-
ABL and CDK5, and regulates CDK5 tyrosine phosphorylation by c-ABL.
Western blot analyses showed a signiﬁcant increase in CABLES protein
levels in APP/PS1 mice compared with WT mice (p<0.01). DXI-
treated transgenic group showed a signiﬁcant decrease in the expres-
sion of activated proteins involved in c-ABL pathway (p˂0.05). Like-
wise, DXI prevented the inhibition of brain insulin signaling pathway
measured by p-AKT and p-GSK3β analyses, which showed a signiﬁcant
increased phosphorylation compared with non-treated APP/PS1 mice
(p<0.05; p<0.01; Fig. 3C).
Fig. 6. A proposed mechanism where Dexibuprofen
could constitute a potential treatment for AD. DXI
causes a reduction in neuroinﬂammatory process
which decreases three key signaling pathways,
CABLES/c-ABL, hippocampal insulin pathway and
the β-secretase enzyme, which are directly involved
in the production and metabolism of Aβ, TAU
phosphorylation and memory improvement. These
signaling pathways constitute an early target for the
treatment of AD with DXI, probably in a pre-
symptomatic stage which can explain the potential
use of this drug in neurodegenerative diseases.
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3.4. Dexibuprofen improves the cognitive process in APPswe/PS1dE9 mice
In the NOR test, APP/PS1 DXI mice presented a signiﬁcant increase
of DI compared to non-treated transgenic mice, thus indicating drug
enhanced memory eﬀects (p<0.05; Fig. 4A). In addition, no diﬀer-
ences in total exploration time were observed among the experimental
groups (Fig. 4B).
At the molecular level, APP/PS1 treated with DXI for three months
showed a signiﬁcant increase in CREB phosphorylation at serine 133
(Ser 133) in the hippocampus compared to non-treated APP/PS1 mice
(p<0.05). This phosphorylation leads to the transcription of memory
associated genes. Moreover, no signiﬁcant hippocampal alterations in
the levels of protein kinase A (PKA) nor ARC were observed in APP/PS1
mice compared to WT groups (Fig. 5A).
Finally, in order to evaluate synaptic integrity, we investigated
whether the protein levels of the synaptic marker synaptophysin (SYP)
in transgenic mice after a chronic DXI-treatment were modiﬁed. DXI
treatment induced a consistent increase in SYP protein levels of DXI
APP/PS1 mice hippocampus compared with vehicle-treated APP/PS1
mice (Fig. 5B). Thus, these data indicate that DXI treatment could im-
prove the memory process through the p-CREB.
4. Discussion
Several epidemiological studies have reported that chronic use of
NSAIDs reduces the risk for AD [10]. In the same line, the present re-
search demonstrates that a chronic DXI treatment ameliorates learning
and memory deﬁcits in APP/PS1 mice, thus suggesting that DXI could
be an AD modifying drug. DXI exerts signiﬁcant eﬀects on the reduction
of Aβ production, both enhancing Aβ clearance and inhibiting ag-
gregation of Aβ into amyloid plaques, as well as inhibiting TAU phos-
phorylation.
Brain gliosis activation is an important pathological feature of all
neurodegenerative disorders, also AD [30]. Previous preclinical re-
search has reported that activation of microglia and astrocytes is
markedly enhanced and probably correlates with cognitive deﬁcits and
amyloid plaques in the brain of APP/PS1 [31,32]. The results of the
present investigation show that DXI treatment markedly reduces the
activated astrocytes as well as the cytokine expression -mainly TNFα- in
the hippocampus of APP/PS1 mice. Microglia activation and cytokine
increase in brain are important in the onset of AD, since it has been
demonstrated that drugs against TNFα improve AD neuropathology
[17,33]. Therefore, the signiﬁcant reduction of inﬂammatory mediators
observed in DXI treated APP/PS1 mice could partially explain the
neuroprotective properties of this NSAID.
The DXI eﬀect on decreasing brain Aβ accumulation might be at-
tributed to two main factors: 1) the direct APP inhibition and 2) the
inhibition of hippocampal BACE1 expression, thus regulating Aβ pro-
cessing towards amyloidogenic pathways [34]. Furthermore, our results
show that DXI treatment markedly increased IDE expression in the
hippocampus, suggesting that the eﬀect of DXI on lowering Aβ de-
position might also be attributable to its role in promoting Aβ de-
gradation [35].
Besides Aβ pathology, the abnormal increase of the hyperpho-
sphorylated TAU protein, the major component of intracellular neuro-
ﬁbrillary tangles (NFTs), contributes to the development of AD [36].
The results of the current study show that DXI treatment signiﬁcantly
reduced pTAU at multiple sites in the hippocampus of APP/PS1 mice, a
matter of importance given that hyperphosphorylated TAU is directly
implicated in memory dysfunction in AD [23,37]. However, Kitazawa
and colleagues demonstrated that lipopolysaccharide treatment, a
compound which activates brain microglia, signiﬁcantly exacerbated
the TAU pathology in the 3xTg-AD mice without aﬀecting APP pro-
cessing [37–39]. Thus, microglia activation could directly aﬀect TAU
phosphorylation, independently of Aβ modulation.
To further elucidate the mechanism for the DXI-dependent
reduction in TAU phosphorylation, we assessed the changes in activa-
tion of CDK5 and GSK3β -the two major kinases that phosphorylate
TAU- by using speciﬁc antibodies [40]. It has been demonstrated that
CDK5 activity is regulated by its phosphorylation at Tyr15 site, ex-
hibiting an increased CDK5 activation in APP/PS1 mice [40,41].
Moreover, in vitro and in vivo studies have shown that active c-ABL, a
kinase triggered by Aβ, promotes CDK5 phosphorylation at Tyr15 site
and increases its activity leading to TAU phosphorylation [41]. We
found that DXI treatment reduced the elevated levels of pCDK5 at Tyr15
site in the brain of APP/PS1 mice, suggesting that DXI attenuates TAU
hyperphosphorylation through its inhibitory eﬀect on CDK5 signal
pathway. Moreover, it is known that c-ABL phosphorylates CDK5 on
Y15 through the adaptor protein CABLES, thus stimulating the CDK5
kinase activity [41]. Furthermore, it has been reported that c-ABL can
be activated in response to oxidative stress, DNA damage and in-
ﬂammation. Our results showing a signiﬁcant reduction of c-ABL, C-
ABLES, pCDK5 (Y15) and some TAU phosphoepitopes in the DXI
treated group are in accordance to this data. These ﬁndings might be
explained by the reduction in the levels of cytokines and interleukins
-especiﬁcally TNFα- involved in the activation of c-ABL. Moreover,
since our results indicate that DXI could alter the CDK5 pathway by
decreasing the inﬂammatory response, CDK5 could be the link between
glial activation and TAU phosphorylation. Therefore, c-ABL might be
upstream of CDK5 activation and DXI might attenuate TAU phosphor-
ylation through inhibiting the CDK5 signal pathway TNFα/c-ABL/C-
ABLES/CDK5.
The role of impaired brain insulin signaling in the pathogenesis of
AD is also supported by several recent preclinical studies showing im-
provements in cognition, memory and TAU phosphorylation by treat-
ment with intranasal insulin. Our results have shown that DXI treat-
ment increased both pGSK3β and pAKT activity in APP/PS1.
Our results also demonstrate that DXI reverses cognitive deﬁcits in
the APP/PS1 mice, since the performance of the NOR test was improved
in the DXI treated group against the non-treated APP/PS1. In previous
studies, Trinchese and colleagues reported that synaptic plasticity and
memory loss in APP/PS1 mice occur as early as 3–4 months of age and
it is independent of plaque formation [42,43]. Thus, targeting synapses
and molecular mechanisms of memory, mainly CREB phosphorylation,
could be a suitable target for AD improvement, since synaptic dys-
function occurs independently of plaque formation.
Previous studies reported that loss of synapses is one of the main
neuropathological hallmarks of AD, which strongly correlates with the
cognitive decline [14]. The beneﬁcial eﬀects of DXI on cognitive im-
provement in the APP/PS1 mice are likely attributable to the combined
eﬀects of the reduction in pro-inﬂammatory molecules and BACE1, as
well as the increase in p-CREB expression and synaptic integrity [44].
PKA is the main kinase involved in CREB phosphorylation and
contributes to the process of memory formation by regulating the
classical cAMP/PKA/CREB pathway [44]. However, no-changes on PKA
expression were observed in the hippocampus of APP/PS1 mice. Since
BACE 1 is involved in the regulation of CREB phosphorylation, we
suggest that DXI treatment could increase pCREB levels by targeting
BACE1 [45].
We considered APP/PS1 transgenic mice the best model to study
DXI eﬀects and mechanisms involved in AD, since these animals show
amyloid plaques deposits and TAU hyperphosphorylation.
Notwithsantding, no animal model reproduces all the features involved
in the human AD. Moreover, only female mice were used in this study,
since it has been demonstrated that they present higher vulnerability to
AD in comparison with age-matched males.
5. Conclusions
In conclusion, this study shows that DXI could exert multiple ben-
eﬁcial eﬀects against AD, both decreasing the inﬂammatory response
and the levels of amyloid plaques and neuroﬁbrillary tangles, while
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enhancing the memory. Thus, our results provide more evidence
showing that NSAIDs could reduce AD risk through multiple mechan-
isms. In addition, this is the ﬁrst study reporting new targets that could
clarify the mechanisms involved in DXI enhancement of memory and
cognitive performance in a familial AD animal model. These mechan-
isms are TNFα/c-ABL/CDK5/TAU inhibition, insulin signaling activa-
tion and BACE1/SYP/p-CREB modulation (Fig. 6).
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